Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into an Agreement with an unnamed pharmaceutical company ("PharmCo") to investigate Lexaria's DehydraTECH technology with one or more proprietary PharmCo molecules.

Today's announcement is separate from, and has no relationship with, Lexaria's two Material Transfer Agreements already existing with other pharmaceutical companies.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.